News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
Celsion (CLSN) Highlights Recent Pipeline Developments For Its GEN-1 Immunotherapy Program And Provides Business Update 2/12/2016
Armed with $50 Million from Google (GOOG), Celgene (CELG) and More, ARMO BioSciences Eyes Next-Gen Cancer Drug Combos 2/11/2016
Achillion (ACHN) Initiates Phase I Study Of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor 2/11/2016
BIND Therapeutics (BIND) Release: AZD2811 ACCURINS Data Published In Science Translational Medicine Highlight One Of The First Applications Of Nanomedicine To Molecularly Targeted Cancer Therapies 2/11/2016
Blaze Bioscience Inc. To Present Tumor Paint BLZ-100 At SPIE Photonics West Conference 2/11/2016
Incyte (INCY) Reports 2015 Fourth-Quarter And Year-End Financial Results, Provides 2016 Financial Guidance And Updates Shareholders On Key Clinical Programs 2/11/2016
Human Validation Data Supporting Saronic Biotechnology's Lead Therapeutic SBI1997 Published In The Journal Of Immunotherapy 2/10/2016
Resolve Therapeutics Announces Positive Clinical Data From RSLV-132 Lupus Study 2/10/2016
Heptares Announces Positive Results From Phase 1b Clinical Trial With HTL9936, A First-In-Class Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Dementia And Schizophrenia 2/10/2016
Arrowhead Research Corporation (ARWR) Reports Fiscal 2016 First Quarter Results 2/10/2016
Catabasis Pharma Will Present CAT-1004, A Potential Disease-Modifying Agent In Development For The Treatment Of Duchenne Muscular Dystrophy, At The XIV International Conference On Duchenne And Becker Muscular Dystrophy 2/10/2016
Cytori Therapeutics (CYTX) Release: Scleroderma Two Year Data To Be Presented At The 4th Systemic Sclerosis World Congress 2/10/2016
Catabasis Pharma Will Present CAT-1004, A Potential Disease-Modifying Agent In Development For The Treatment Of Duchenne Muscular Dystrophy, At The XIV International Conference On Duchenne And Becker Muscular Dystrophy 2/10/2016
Sosei Subsidiary Heptares Announces Positive Results From Phase 1b Clinical Trial With HTL9936, A First-In-Class Selective Muscarinic M1Receptor Agonist For Improving Cognition In Dementia And Schizophrenia 2/10/2016
AstraZeneca PLC (AZN)'s Immunotherapy Lung Cancer Combo Treatment Sees Breakthrough in Early Stage Trial 2/9/2016
DNAtrix, Inc.'s Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation For Treating Malignant Brain Tumors 2/9/2016
ZIOPHARM, Inc. Announces First Patient Enrolled In Phase I Study Of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy For Advanced Lymphoid Malignancies 2/9/2016
ADC Therapeutics Doses First Patient In Phase I Trial Of ADCT-301 Trial In Acute Myeloid Leukemia 2/9/2016
Myasthenia Gravis: Curavac Launches Phase 1b Study In Patients 2/9/2016
Patient Died in Akashi's Halted Trial 2/8/2016
AstraZeneca PLC (AZN)’s Combination Of Durvalumab With Tremelimumab Shows Clinical Activity In Non-Small Cell Lung Cancer Irrespective Of Pd-L1 Status 2/8/2016
ERYtech Pharma Announces 2016 Financial Calendar 2/8/2016
Sangamo (SGMO) Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I 2/8/2016
Elios Therapeutics, LLC Release: Novel Cancer Vaccine In Combination With Check Point Blockades Holds Promise 2/5/2016
Nordic Nanovector To Present At The Swiss-Scandinavian Bio-Business Seminar On 10 February 2016 2/5/2016
Lab Criticized as 'Slow to React' in Bial's Fatal Drug Trial 2/5/2016
Can-Fite BioPharma (CFBI) To Present At BIO CEO & Investor Conference In New York City On February 8, 2016 2/5/2016
Ignyta (RXDX) Announces Initiation Of Phase 1/1b Clinical Trial Of Taladegib In Combination With Paclitaxel By Cancer Research UK 2/4/2016
Johnson & Johnson (JNJ) Hands Over In-House Rival BetaLogics to ViaCyte, Gives Updates on Stem Cell Diabetes Trial 2/4/2016
Asterias Biotherapeutics Receives Orphan Drug Designation For AST-OPC1 For The Treatment Of Acute Spinal Cord Injury 2/4/2016
CollPlant Reports Positive Final Trial Results For Vergenix STR, Indicated For The Treatment Of Tendinopathy 2/4/2016
ERYtech Pharma To Present At Upcoming Investor Conferences 2/4/2016
US Oncology Research Translational Oncology Program Enrolls 2,000th Patient In Leading-Edge Phase I Clinical Trials 2/4/2016
Rock Creek Pharmaceuticals Announces Inhibition Of STAT 3 Activation, A Key Marker Of Inflammation, In Phase I Clinical Trial In Europe 2/3/2016
MabVax Therapeutics, Inc. To Present At BIO CEO & Investor Conference 2/3/2016
Xencor To Present At Two Upcoming Conferences In February 2/3/2016
Cytori Therapeutics, Inc. (CYTX) Cell Therapy Safe And Potentially Effective In EU Phase I Erectile Dysfunction Trial 2/3/2016
Alexion (ALXN) Reports Fourth Quarter And Full Year 2015 Results And Provides Financial Guidance For 2016 2/3/2016
BioTime (BTX) To Present At Three Investor Conferences In February 2/2/2016
OXIS International, Inc. (OXIS) Chairman And CEO Tells Shareholders Biotech Company Making 'Substantial Progress' With Lead Cancer Drug, Drawing Closer To NASDAQ Listing 2/2/2016
Asterias Biotherapeutics To Present At The 18th Annual BIO CEO & Investor Conference 2/2/2016
Kamada Ltd. (KMDA) Reports 2015 Fourth Quarter And Full Year Financial Results 2/2/2016
With Almost $200 Million in the Bank, WAVE Life Sciences (WVE) Plans Six Clinical Programs in Three Years 2/1/2016
Pulmatrix Initiates European Pilot Bioequivalence Study Of PUR0200 For COPD 2/1/2016
MabVax Therapeutics, Inc. Receives FDA Authorization For Phase I Clinical Trial With 89Zr-Humab-5B1 As PET Imaging Agent For Pancreatic Cancer 2/1/2016
Cerulean Pharma Inc. (CERU) To Present At Two Upcoming Conferences 2/1/2016
Enanta Pharmaceuticals, Inc. To Present At The LEERINK Partners 5th Annual Global Healthcare Conference 2/1/2016
Lpath (LPTN) Completes Dosing In The Lpathomab Phase 1 Safety Study 2/1/2016
Mymetics Announces Discontinuation of the RSV Collaborative Project 1/29/2016
ImmunoGen (IMGN) Reports Second Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update 1/29/2016
Adocia And Eli Lilly (LLY) Initiate Phase 1b Study Evaluating Ultra-Rapid Insulin BioChaperone Lispro U100 In Healthy Japanese Subjects 1/29/2016
Ablynx (ABLYF) To Receive €8 Million Milestone As Boehringer Ingelheim Starts First Patient Study With A Bi-Specific Nanobody In Oncology 1/29/2016
Bristol-Myers Squibb (BMY) Reports Fourth Quarter And Full Year 2015 Financial Results 1/28/2016
Axim Biotech Featured by Reuters: Biotech Receives Cannabis Strains at "Discount for Gum to Treat Multiple Sclerosis" 1/28/2016
Fate Therapeutics (FATE) Announces FDA Clearance Of Investigational New Drug Application For Protmune For Prevention Of Acute Gvhd And CMV Infection 1/27/2016
ImmunoCellular Therapeutics, Ltd (IMUC) Enters Into A Sponsored Research Agreement With The University of Maryland, Baltimore To Pursue Multiple Enhancements Of Its Cancer Immunotherapy Platforms 1/27/2016
AVAX Technologies, Inc. (AVXT) Announces Results Of Its OVAX, Ovarian Cancer Vaccine, Phase 1/2 Clinical Trial In Patients With Relapsed Stage III Or IV Ovarian Cancer. 1/27/2016
Stemedica Cell Technologies, Inc. Announces Completion Of Enrollment In Phase I/Ila Clinical Trial For Ischemic Stroke 1/27/2016
Biogen (BIIB) 2015 Revenues Increase 11% To $10.8 Billion 1/27/2016
Clovis Oncology (CLVS) Initiates Immunotherapy Combination Trial 1/27/2016
Akashi Halts DMD Clinical Trial, Third Company to Recently Have Problems With DMD Drug Trials 1/26/2016
Phase I Trial Data For Cornerstone Pharmaceuticals, Inc.' CPI-613 In Combination With Modified Fluorouracil, Leucovorin, Irinotecan, And Oxaliplatin (mFOLFIRINOX) In Metastatic Pancreatic Adenocarcinoma To Be Presented At The Annual Gastrointestinal Cancers Symposium 1/26/2016
Regen BioPharma Submits Application To FDA For Orphan Drug Designation For Its HemaXellerate Product 1/26/2016
Encore Vision, Inc. Announces Completion Of Target Enrollment In Clinical Study Evaluating Topical EV06 For The Treatment Of Presbyopia 1/25/2016
Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured At The ASCO 2016 Gastrointestinal Cancers Symposium 1/25/2016
Affimed Therapeutics AG (AFMD) Enters Into Collaboration With Merck & Co. (MRK) To Evaluate AFM13 In Combination With KEYTRUDA (Pembrolizumab) For Patients With Hodgkin Lymphoma 1/25/2016
Catabasis Pharmaceuticals, Inc. Announces Positive Top-Line Results From Part A Of The Movedmd Trial, A Phase I/II Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy 1/25/2016
Sunovion Pharmaceuticals Inc. Announces Results From A Study Evaluating The Abuse Potential Of Investigational Drug Dasotraline 1/25/2016
Alkermes (ALKS) Announces Initiation Of Phase 1 Clinical Study Of New CNS Drug Candidate ALKS 7119 1/25/2016
CARsgen Therapeutics Completes $30 Million Series B Financing 1/25/2016
Sneak Peak of Five Prime (FPRX)'s Prelim Phase I Tumor Data Leaves Investors Happy 1/22/2016
NewLink Genetics (NLNK) Presents Phase Ib Data Of Indoximod In Combination With Gemcitabine/Nab-Paclitaxel For Patients With Metastatic Pancreatic Cancer That Show Encouraging Durable Responses With Delayed Pattern 1/22/2016
Helix Biopharma (TSX:HBP) Initiates Enrollment In The Second Dosing Cohort Of U.S. Combination Treatment Study Of Its Lung Cancer Drug Candidate L-DOS47 1/22/2016
Cellceutix (CTIX) Releases Data Used In Receiving FDA Orphan Drug Designation Of Kevetrin For Pancreatic Cancer 1/22/2016
Leap Therapeutics Presents Positive Data From Phase 1 Study Of DKN-01 In Combination With Paclitaxel In Relapsed Or Refractory Cancer Of The Esophagus Or Gastro-Esophageal Junction 1/22/2016
Asterias Biotherapeutics Announces Completion Of Transfer Of AST-VAC2 Manufacturing Process To Cancer Research UK As Milestone Towards Initiating Phase 1/2 Clinical Trial 1/21/2016
Halozyme (HALO) Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE Technology 1/21/2016
Questions Remain as to What Caused the Bial Trial Tragedy in France 1/20/2016
GenVec (GNVC) in Limbo Awaiting Novartis AG (NVS)'s Decision on Status of Lead Drug CGF166 1/20/2016
Immunocore Starts Clinical Trial With IMCgp100 In Combination With MedImmune (AZN) Immunotherapies Durvalumab And Tremelimumab 1/20/2016
Oncolytics Biotech Inc. (ONC.TO) Announces First Patients Treated In Phase 1b Study In Advanced Pancreatic Cancer 1/20/2016
NewLink Genetics (NLNK) To Present Phase 1b Data On Indoximod In Combination Therapy In Patients With Metastatic Pancreatic Cancer At ASCO GI 1/20/2016
AmpliPhi Biosciences Corporation (APHB) Announces Dosing Of First Patient In Phase I Clinical Trial Of AB-SA01 1/20/2016
Sunshine Biopharma, Inc. Is Moving Forward With Its Development Plans For Adva-27a Anticancer Compound 1/20/2016
Oncolytics Biotech Inc. (ONC.TO) Announces First Patients Treated In Phase 1b Study In Advanced Pancreatic Cancer 1/19/2016
Profectus BioSciences, Inc. Initiates Ebola Vaccine Phase 1 Clinical Trial 1/19/2016
Abide Therapeutics Appoints Richard N. Kender To Board Of Directors 1/19/2016
Karyopharm (KPTI) Initiates Second Generation SINE Compound Clinical Trial in Multiple Myeloma 1/19/2016
Merck & Co. (MRK) Release: Data For KEYTRUDA (pembrolizumab) In A Range Of Gastrointestinal Cancers To Be Presented At 2016 Gastrointestinal Cancers Symposium 1/19/2016
MabVax Therapeutics, Inc. Executes A Debt Facility For Up To $10 Million 1/19/2016
Allakos Successfully Completes Dosing In Phase 1 Clinical Trial Of AK001 And Announces Expansion Of Its Executive Team 1/19/2016
Arrowhead Research Corporation (ARWR)'s ARC-AAT Granted European Medicines Agency Orphan Drug Designation 1/19/2016
Man in Coma Dies After Bial's Botched Drug Trial in France, Five Remain Hospitalized 1/19/2016
Biogen (BIIB)'s Promising Pipeline Underscores CEO’s High-Risk Strategy 1/19/2016
Drugmaker Unnamed as Botched Trial in France Leaves One Patient Brain Dead and Five Hospitalized 1/18/2016
Strategia Therapeutics Initiates A Phase 1 Clinical Trial Of The Radioimmunotherapeutic "FF-21101" For FUJIFILM In Patients With Advanced Cancers 1/18/2016
Hutchison China MediTech (Chi-Med) Initiates HMPL-523 Phase I Clinical Trial In Hematological Cancer In Australia 1/15/2016
Karyopharm (KPTI) Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma 1/14/2016
Spark Therapeutics (ONCE)' Ambitious Goals Include 10 Gene Therapy Programs by 2018 1/13/2016
Adamas Pharmaceuticals (ADMS) Provides Review Of 2015 And Projected Future Milestones 1/13/2016
Ionis (IONS) Announces That GlaxoSmithKline (GSK) Has Initiated A Phase 1 Study Of IONIS-HBV-L Rx 1/13/2016
Booming Moderna Eyes Six Human Trials in 2016, Inks Deals with AstraZeneca PLC (AZN), Merck & Co. (MRK) and Signed Huge Lease in Cambridge for R&D Growth 1/12/2016
SELLAS Life Sciences Announces Preliminary Positive WT1 Cancer Vaccine Clinical Results In Multiple Myeloma Patients 1/12/2016
FORMA Enrolls First Patient In Phase I Study Of FT-1101 In Advanced Hematological Malignancies 1/12/2016
BioLineRx Ltd. Announces Collaboration With MSD To Investigate The Combination Of KEYTRUDA (pembrolizumab) And BL-8040 In Pancreatic Cancer 1/12/2016
Ionis (IONS) Revises 2015 Financial Guidance And Provides Pipeline Update In Conjunction With J.P. Morgan Conference 1/12/2016
Moderna Announces Transition To A Clinical Stage Company, Provides Business Update And Outlines 2016 Strategic Priorities 1/12/2016
Can-Fite BioPharma (CFBI) Announces 2016 Clinical Milestones For Its Pipeline Of Drugs In Six Indications 1/11/2016
Bellicum (BLCM) Announces Submission Of BPX-701 And BPX-601 Clinical Trial Protocols For Review By The NIH RAC 1/11/2016
Immune Design Corporation (IMDZ) Receives Orphan Drug Designation From The U.S. FDA For Complementary Components Of CMB305 1/11/2016
DURECT Corporation (DRRX) Announces Initiation Of DUR-928 Dosing In Patients 1/11/2016
Xcovery Announces Updated Clinical Data On X-396 In Patients With ALK+ Non-Small Cell Lung Cancer At The 4th Xcovery-IASLC International Joint Conference 1/11/2016
Lycera Announces Celgene Has Exercised Its Option To License Portfolio Of Ex Vivo RORgamma Agonist Compounds Under Global Strategic Collaboration 1/11/2016
aTyr Pharma Provides Corporate Update And Outlook For 2016 1/11/2016
PTC Therapeutics (PTCT) Outlines Business Priorities For The Development And Commercialization Of Translarna And Progress Of The Company Pipeline 1/11/2016
Eicosis, LLC Receives $4 Million To Develop Novel Treatment For Diabetic Neuropathic Pain 1/11/2016
Rebiotix And Washington University Treat First Patient With Urinary Tract Infection Utilizing Investigational RBX2660 To Potentially Reverse Multidrug Resistant Organisms 1/11/2016
Cidara Therapeutics (CDTX) Announces Positive Data From Multiple Dose Phase I Clinical Trial Of CD101 IV 1/11/2016
Sangamo BioSciences (SGMO) Highlights 2016 Catalysts At The 34th Annual J.P. Morgan Healthcare Conference 1/11/2016
Infinity Pharmaceuticals Inc. (INFI) Provides Key 2016 Goals And Financial Guidance 1/11/2016
OXIS International, Inc. (OXIS) Eliminates Debt In Restructuring Deal, Will Move Forward With Phase 1/Phase 2 Clinical Trial Of Cancer Drug 1/11/2016
Enanta Pharmaceuticals, Inc. Announces New R&D Initiatives In Hepatitis B Virus And Respiratory Syncytial Virus And Plan To Provide Data Updates On Programs In NASH And HCV At The 34th Annual J.P. Morgan Healthcare Conference 1/11/2016
ImmunoGen (IMGN) Announces Recent Product Program Advancements And Anticipated 2016 Events In Advance Of J.P. Morgan Healthcare Conference 1/11/2016
Protagonist Therapeutics Initiates Phase 1 Study With Oral Peptide PTG-100 1/8/2016
NW Bio (NWBO) Issues Statement On Adverse Market Conditions And NW Bio Stock Decline 1/8/2016
Valor Biotherapeutics Announces First Patient Treated In Phase 1 Study Of IGN002 1/8/2016
Kolltan Pharmaceuticals Inc. Provides Update On Clinical Pipeline, Corporate Developments And Near-Term Milestones 1/8/2016
PTC Therapeutics (PTCT) Release: Spinal Muscular Atrophy Program Advances With Additional Product Candidate Entering Clinical Development 1/8/2016
Adaptimmune (ADAP) Expands T-Cell Engineering Expertise To Develop Affinity Enhanced T-Cell Therapies For Autoimmune Indications 1/7/2016
Protalex, Inc. (PRTX) Announces First Patient Dosed In European Phase Ib Study Of PRTX-100 For Immune Thrombocytopenia 1/7/2016
NIH Initiates Phase 1 Trial Of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology 1/7/2016
Celsion (CLSN) Reports Translational Research Data From Its Phase 1b Study Of GEN-1 Immunotherapy In Recurrent Ovarian Cancer 1/7/2016
Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results For Aerucin For Treating Hospital-Acquired And Ventilator-Associated Pneumonia 1/7/2016
aTyr Pharma Appoints Sanuj Ravindran, M.D., As Chief Business Officer 1/7/2016
Regulus (RGLS) Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 1/7/2016
Apogenix Receives First Milestone Payment From CANbridge Licensing Agreement And Signs Amendment To Include Taiwan 1/7/2016
Eureka Therapeutics Announces Exclusive License Agreement Between Memorial Sloan-Kettering Cancer Center And Juno (JUNO) For Use Of A Novel, Fully-Human MUC16 Binder In CAR T Cell Immunotherapy 1/7/2016
uniQure (QURE) Announces Preliminary Topline Results From Low-Dose Cohort In Hemophilia B Phase I/II Gene Therapy Clinical Trial 1/7/2016
uniQure (QURE) Announces Conference Call And Webcast To Discuss Topline Results From Low-Dose Cohort In Hemophilia B Phase I/II Gene Therapy Clinical Trial 1/7/2016
Zynerba (ZYNE) Announces Positive Initial Results From ZYN002 CBD Gel Phase I Single Rising Dose Trial And Initiation Of Phase I Multiple Rising Dose Trial 1/7/2016
Naia Rare Diseases Inc., A Subsidiary Of Naia Limited, Forms Scientific Advisory Board Comprised Of Internationally Renowned Experts And Scientists 1/7/2016
CANbridge Completes Chinese Glioblastoma Biomarker Study For Lead Candidate, CAN008 1/7/2016
Clinical Trial Transparency Highlighted During Leadership Conference 1/7/2016
MabVax Therapeutics, Inc. Files IND For A Phase I Clinical Trial With 89Zr-Humab-5B1 1/6/2016
argenx Announces Initial Results From A Phase 1 Single Ascending Dose Study Of ARGX-113 In Healthy Volunteers 1/6/2016
Xcovery To Present X-396 In ALK+ Non-Small Cell Lung Cancer Study Data At 4th Annual AACR-IASLC International Joint Conference 1/6/2016
Sensorion Receives Approval From The UK Drug Agency To Initiate Clinical Trial Of SENS-218 1/6/2016
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At Biotech Showcase 2016 In San Francisco 1/6/2016
Washington University in St. Louis Initiates Clinical Study Of Verastem (VSTM)’s VS-6063 In Combination With Merck & Co. (MRK)’s Pembrolizumab And Gemcitabine In Pancreatic Cancer 1/6/2016
Embera NeuroTherapeutics, Inc. Announces Successful Completion Of Phase 1 Clinical Trial Testing EMB-001, A Potential Novel Treatment For Addictions 1/6/2016
Seres Therapeutics To Present At 34th Annual J.P. Morgan Healthcare Conference 1/6/2016
Seres Therapeutics Announces Appointment Of Wael Hashad As Chief Commercial Officer 1/6/2016
Blueprint Medicines (BPMC) Strengthens Executive Leadership Team 1/6/2016
ImaginAb, Inc.'s PSMA Imaging Agent Detects More Lesions Compared To Standard Imaging Methods For Detection Of Prostate Cancer In Phase I/Ila Study 1/6/2016
DURECT Corporation (DRRX) Announces Positive Phase 1 Data For DUR-928 1/6/2016
eFFECTOR Initiates Dosing In Phase 1/2 Clinical Trial Of eFT508 In Solid Tumors 1/6/2016
Ionis (IONS) Receives Orphan Drug Designation From The US FDA For IONIS-HTT Rx For The Treatment Of Patients With Huntington's Disease 1/5/2016
Rhythm And Camurus Announce License Agreement For Extended Release Fluidcrystal Setmelanotide 1/5/2016
Cellectar Biosciences  (NVLT) Announces Positive Data From Phase I Therapeutic Trial Of CLR 131 In Multiple Myeloma 1/5/2016
True North Therapeutics To Present Clinical Data For Lead Product Candidate At J.P. Morgan Healthcare Conference 1/5/2016
DelMar Pharma To Present At The Biotech Showcase 2016 On January 12, 2016 1/5/2016
MabVax Therapeutics, Inc. Announces FDA Authorization To Proceed With Humab-5B1 In A Phase I Clinical Trial For The Treatment For Pancreatic Cancer 1/4/2016
Yisheng Biopharma Announces Positive Results Of Phase I Clinical Trial Of A Novel Rabies Vaccine With PIKA Adjuvant 1/4/2016
BioLineRx Ltd. To Present At Biotech Showcase 2016 Conference In San Francisco 1/4/2016
AveXis Announces Completed Enrollment Of Phase I Clinical Trial For AVXS-101 In Spinal Muscular Atrophy Type 1 1/4/2016
Cellprothera Release: Cellular Regenerative Therapy Greeted By French Minister Of Health 1/4/2016
Global Therapeutics Receives FDA Orphan Drug Designation For GBT440 In Sickle Cell Disease 12/31/2015
Rich Pharma Receives FDA Approval For A Phase 1/2 Study In AML & MDS 12/28/2015
Cellectis (ALCLS) Files First Clinical Trial Application For UCART19, An Allogeneic Gene Edited CAR T-Cell Product For Hematological Malignancies 12/28/2015
Strategia Therapeutics Announces Progress In A Phase 1 Clinical Trial Of The Anti-Cancer Agent "FF-10501-01" For FUJIFILM In Patients With Advanced Hematologic Malignancies 12/28/2015
RestorGenex (RESX) and Diffusion Pharma Merge to Form Wholly-Owned Oncology Subsidiary 12/28/2015
KaloBios (KBIO) Fires Martin Shkreli, UC Davis Suspends Leukemia Trial Due to Shkreli 12/23/2015
Select Biosciences Announces Dosing Of First Patient In Phase 1b Clinical Trial Of SEL-212, Designed To Be The First Non-Immunogenic Biologic Treatment For Gout 12/23/2015
Flamel Technologies (FLML) Announces Positive Interim Results Of A First-In-Man Clinical Trial With MedusaExenatide 12/22/2015
Dicerna (DRNA) Begins Dosing In First Clinical Trial Of Therapy For Primary Hyperoxaluria Type 1 (PH1) In Healthy Volunteers 12/22/2015
HUYA Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 12/22/2015
CSL Behring Submits Marketing Authorization Application To The European Medicines Agency For RViii-SingleChain For Patients With Hemophilia A 12/22/2015
Boehringer Ingelheim Receives FDA Breakthrough Therapy Designation for BI 1482694 12/21/2015
Entia Biosciences Begins Clinical Study Of Proprietary Ergod2 Medical Food Product To Demonstrate Improved Health For The More Than 25 Million Chronic Kidney Disease Sufferers In The U.S. 12/21/2015
NW Bio (NWBO) Announces Annual Meeting Results, Re-Election of Directors 12/21/2015
Alnylam (ALNY) Files Clinical Trial Application (CTA) For ALN-GO1, An Investigational Rnai Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1) 12/21/2015
DS Biopharma Announces Successful Completion Of A Phase I Safety Study With Bioactive Lipid DS102 Which Is Targeting NASH And IPF 12/18/2015
Regulus (RGLS) Release: RG-125(AZD4076), A microRNA Therapeutic Targeting microRNA-103/107 Being Developed For The Treatment Of NASH In Patients With Type 2 Diabetes/Pre-Diabetes, Enters Phase I Clinical Development 12/18/2015
Boehringer Ingelheim Presents Strong Lung Cancer Portfolio And Long-Awaited Head-To-Head Data Of afatinib Compared To gefitinib At ESMO Asia 2015 Congress 12/18/2015
Catabasis Pharmaceuticals, Inc. Completes Enrollment For Part A Of The Movedmdsm Trial, A Phase I/II Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy 12/18/2015
Neurocrine Biosciences (NBIX) Announces Successful Completion Of Phase Ib T-Force Study Of VMAT2 Inhibitor NBI-98854 In Adolescents And Children With Tourette Syndrome 12/17/2015
Mirati Therapeutics  (MRTX) Doses First Patient In Expansion Cohorts Of MGCD516 Phase 1b Trial In Genetically Selected Patients 12/17/2015
Cellect Receives Approval To Commence Human Trial In Healthy Volunteers At The Schneider Medical Center 12/17/2015
Vaxart, Inc. Announces Enrollment Of First Patient In Influenza B Phase I Trial 12/17/2015
Adaptimmune (ADAP) Announces Initiation Of Study To Evaluate Its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 In Patients With NSCLC, The Most Common Form Of Lung Cancer 12/17/2015
Symic Receives New U.S. Patent For Osteoarthritis Program 12/16/2015
Catalyst Pharmaceuticals (CPRX) Announces Top-Line Results In Phase 1(B) Trial Of CPP-115 12/16/2015
The Medicines Company (MDCO) Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy 12/15/2015
GliaCure Completes Successful Proof Of Concept Phase 1b Clinical Trial In Alzheimer's Disease 12/15/2015
GliaCure Completes Successful Proof Of Concept Phase 1b Clinical Trial In Alzheimer's Disease 12/15/2015
Regen BioPharma Receives FDA Clearance To Initiate Clinical Trial Of Hemaxellerate 12/15/2015
Bird Rock Bio Announces Corporate Name Change From RuiYi (formerly Anaphore) 12/15/2015
REMD Biotherapeutics To Begin Phase 1B Clinical Study Of REMD-477 For Patients With Type 1 Diabetes 12/15/2015
Bayer (BAY) Looks to Become Player in Oncology Treatments 12/14/2015
Celsion (CLSN) Announces Presentation Of DIGNITY Phase I/II ThermoDox Data At The 2015 San Antonio Breast Cancer Symposium 12/14/2015



//-->